Thus, there is a huge demand for the rational development of PI3K/AKT/mTOR pathway inhibitors, particularly for cancer subtypes with alterations in this pathway that could benefit from combination therapy (Guimarães et al., 2015). This evidence concerns the gene AKT1 and cancer.